COMPUVAC - Ration design and standardized evaluation of novel genetic vaccines. (FP6-LIFESCIHEALTH) (2005-01-01 - 2008-12-31) (»add to infobox)

David KLATZMANN, David KLATZMANN, Anatoly SHARIPO, Jacek BLAZEWICZ, Thomas BROCKER, François-Loïc COSSET, Gary Thomas JENNINGS, Tina DALIANIS, Charlotte FRISEN, Alberto EPSTEIN, Stefan KOCHANEK, Penelope MAVROMARA, Albertus Dominicus Marcellinus Erasmus OSTERHAUS, Paul PUMPENS, Kestutis SASNAUSKAS, Rudolf Martin ZINKERNAGEL

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR101 - Paris) (France), UNIVERSITE PIERRE ET MARIE CURIE - PARIS VI (FR101 - Paris) (France), ASLA BIOTECH LTD (LV006 - Riga) (Latvia), POLITECHNIKA POZNANSKA POZNAN UNIVERSITY OF TECHNOLOGY PUT (PL415 - Miasto Poznan) (Poland), LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE212 - München, Kreisfreie Stadt) (Germany), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR101 - Paris) (France), CYTOS BIOTECHLOLOGY AG (CH04 - Zürich) (Switzerland), KAROLINSKA INSTITUTET (SE010 - Stockholms län) (Sweden), EPIXIS SA (FR101 - Paris) (France), UNIVERSITE CLAUDE BERNARD LYON 1 (FR716 - Rhône) (France), UNIVERSITAET ULM (DE144 - Ulm, Stadtkreis) (Germany), HELLENIC PASTEUR INSTITUTE (GR300 - Attiki) (Greece), ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (NL335 - Groot-Rijnmond) (Netherlands), LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE (LV006 - Riga) (Latvia), INSTITUTE OF BIOTECHNOLOGY (LT003 - Klaipedos apskritis) (Lithuania), UNIVERSITAET ZUERICH (CH04 - Zürich) (Switzerland)

Recombinant viral vectors and virus-like particles are considered the most promising vehicles to deliver antigens in prophylactic and therapeutic vaccines against infectious diseases and cancer. Several potential vaccine designs exist but their cost-effective development cruelly lacks a standardised evaluation system. On these grounds, COMPUVAC is devoted to (i) rational development of a novel platform of genetic vaccines and (ii) standardisation of vaccine evaluation. COMPUVAC assembles a platform of viral vectors and virus-like particles that are among today's most promising vaccine candidates and that are backed up by the consortium's complementary expertise and intellectual property, including SMEs focusing on vaccine development. COMPUVAC recognises the lack of uniform means for side-by-side qualitative and quantitative vaccine evaluation and will thus standardise the evaluation of vaccine efficacy and safety by using "gold standard" tools, molecular and cellular methods in virology and immunology, and algorithms based on genomic and proteomic information. "Gold standard" algorithms for intelligent interpretation of vaccine efficacy and safety will be built into COMPUVAC's interactive Genetic Vaccine Decision Support System, which should generate (i) vector classification according to induced immune response quality, accounting for gender and age, (ii) vector combination counsel for prime-boost immunisations, and (iii) vector safety profile according to genomic analysis. Since one of our "gold standard" antigens is the West Nile virus (WNV) envelope protein, an additional aim of COMPUVAC is to generate a candidate vaccine against WNV. As end products, our vector platform and "gold standard" tools, methods and algorithms will be available to the scientific and industrial communities as a toolbox and interactive database which standardised nature should contribute to cost-effective development of novel vaccines with validated efficacy and safety profile

PERSONS (16/16)

RELATED NAVIGATION AREA(S) (3/3)